Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine

Anthony D. Ho; Ch. Schwarz; W. Hunstein

doi:10.1016/0145-2126(85)90159-6

ScienceGate Book Chapters

JOURNAL ARTICLE

Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine

Anthony D. Ho Ch. Schwarz W. Hunstein

Year: 1985 Journal: Leukemia Research Vol: 9 (10)Pages: 1293-1298 Publisher: Elsevier BV

DOI: 10.1016/0145-2126(85)90159-6

Get Full-Text PDF Get Analytical Report

Keywords:

Regimen Medicine Myelodysplastic syndromes Myeloid leukemia Internal medicine Leukemia Chemotherapy Acute leukemia Myeloid Oncology Cytarabine Gastroenterology Bone marrow

Metrics

Cited By

0.44

FWCI (Field Weighted Citation Impact)

Refs

0.61

Citation Normalized Percentile

Is in top 1%

Is in top 10%

Topics

Acute Myeloid Leukemia Research

Health Sciences → Medicine → Hematology

Hematopoietic Stem Cell Transplantation

Health Sciences → Medicine → Hematology

Acute Lymphoblastic Leukemia research

Health Sciences → Medicine → Public Health, Environmental and Occupational Health

Treatment of acute myeloid leukemia developing after a myelodysplastic phase with low dose arabinosyl cytosine

Metrics

Topics

Related Documents

Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemia

Low‐dose arabinosyl cytosine in acute leukemia after a myelodysplastic syndrome and in elderly leukemia

Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome by Low Dose Cytosine Arabinoside

Low Dose Cytosine Arabinoside Therapy in Myelodysplastic Syndrome and Acute Myeloid Leukemia

Low-dose cytosine-arabinoside in the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)